New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

Andreas Kjaer; Morten Persson; Michael Ploug

New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

Andreas Kjaer (Opfinder), Morten Persson (Opfinder), Michael Ploug (Opfinder)

Endocrinology and Metabolism

Abstract

There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

Originalsprog	Engelsk
IPC	C07K 16/ 30 A I
Patentnummer	CN104768573
Land/Område	Danmark
Prioritetsdato	03/05/2013
Prioritetsnummer	WO2013DK50126
Status	Udgivet - 8 jul. 2015

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Fingeraftryk

Dyk ned i forskningsemnerne om 'New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors'. Sammen danner de et unikt fingeraftryk.

Citationsformater

New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors. / Kjaer, Andreas (Opfinder); Persson, Morten (Opfinder); Ploug, Michael (Opfinder).
Patentnummer: CN104768573. jul. 08, 2015.

Publikation: Patent

@misc{8f7e108f24f948819f2b98736f69b76d,

title = "New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors",

abstract = "There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.",

author = "Andreas Kjaer and Morten Persson and Michael Ploug",

year = "2015",

month = jul,

day = "8",

language = "English",

type = "Patent",

note = "CN104768573; C07K 16/ 30 A I",

}

TY - PAT

T1 - New 177-lutetium labeled urokinase-type plasminogen activator receptor binding peptide conjugate, useful for treating cancer such as colorectal cancer, prostate cancer, neuroendocrine tumors, brain tumors, breast tumors and ovarian tumors

AU - Kjaer, Andreas

AU - Persson, Morten

AU - Ploug, Michael

PY - 2015/7/8

Y1 - 2015/7/8

N2 - There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

AB - There is provided a 177-Lu labelled peptide for site-specific targeting of the Urokinase Plasminogen Activator Receptor (uPAR) thereby enabling treatment of a cancer disease associated with high uPAR expression; e.g. treatment of colorectal cancer by administering to a patient an effective amount of the 177-Lu labelled peptide.

M3 - Patent

M1 - CN104768573

ER -